Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The oral vaccine based on self-replicating RNA lipid nanoparticles can simultaneously neutralize both SARS-CoV-2 variants alpha and delta

Golamabbas Mohammadi a, Zahra Sotoudehnia Koranni b, Ali Jebali c, *

a Sirjan School of Medical Sciences, Sirjan, Iran
b Medical Education Development Center, Sirjan School of Medical Sciences, Sirjan, Iran
c Department of Medical Nanotechnology, Faculty of Advanced Sciences and Technology, Tehran Medical Science, Islamic Azad University, Tehran, Iran

ARTICLE INFO

Keywords:
Oral vaccine
Self-replicating RNA
B.1.1.7 lineage
B.1.617 lineage

ABSTRACT

The aim of this study was to evaluate self-replicating RNA lipid nanoparticles (saRNA LNPs) to neutralize SARS-CoV-2 variants delta (B.1.617 lineage) and alpha (B.1.1.7 lineage). Before immunization of mice with saRNA LNPs, we saw high expression of S-protein at both mRNA and protein levels after transfection of HEK293T/17 cells with saRNA LNPs. After oral immunization of BALB/c mice with 0.1 – 10 μg saRNA LNPs, a high quantity of SARS-CoV-2 specific IgG and IgA antibodies were seen with a dose-dependent pattern. Importantly, the ratio of IgG2a/IgG1 in serum of vaccinated mice showed Th1/Th2 skewing response. We also found that the secreted antibodies could neutralize SARS-CoV-2 variants delta (B.1.617 lineage) and alpha (B.1.1.7 lineage). Re-stimulated splenocytes of vaccinated mice showed high secretion of IFN-γ, IL-6, and TNF-α. The authors think that although the preclinical study confirmed the efficacy of saRNA LNPs against SARS-CoV-2, the actual efficacy and safety of the oral vaccine must be evaluated in clinical trials.

1. Introduction

Vaccines have different formulations and they are becoming more advanced every day [1]. The use of nucleic acids and nanoparticles are two examples of advanced materials, recently used in vaccine production [2]. Early studies focused on the use of DNA instead of RNA because RNA is less stable than DNA [3]. DNA vaccines produced poor results in human clinical trials [4] and this led to using RNA. Of course, this change in strategy was attributed to the success of cancer immunotherapy by mRNA molecules [5,6]. Moreover, the success of developing mRNA-based COVID-19 vaccines opens a new window to vaccine design [7,8]. There are currently two types of RNA vaccines, including conventional mRNA and self-replicating RNA (saRNA) [9]. These RNAs are produced in vitro and encode pathogen antigens [10].

To produce a saRNA, the sequence of an RNA-dependent RNA polymerase (RDRP) complex from viral origin to amplify saRNA, as well as the 5 and 3 untranslated regions (UTR), is needed for its replication in cytoplasm [11]. After expression of saRNA, activation of immune system is occurred [12]. The production of saRNA vaccines is not very complicated and can be easily integrated into a production line [13]. For example, Hekele et al. designed and produced saRNA vaccine for influenza H7N9 within eight days [14]. There are several formulations that can be used to deliver saRNA vaccines, including cationic polymers [15], lipopolypelexes [16], and lipid nanoparticles (LNPs) [17]. Interestingly, because of the self-replicating property of saRNA, a high immune response can be achieved with low doses of saRNA vaccines [18]. Importantly, the site of action for saRNA is the cytoplasm and it does not require to enter the cell nucleus. Indeed, there is no risk of integration of saRNA into the genome [5,6,19].

Although a variety of COVID-19 vaccines have been developed and some are being used globally, the majority of the population of developing countries still have not been vaccinated because of lack of funds, no infrastructure, and social issues [20]. They need a simple and inexpensive vaccine. Therefore, we sought to design, produce, and evaluate an oral vaccine that could be easily used. The aim of this study was to evaluate saRNA LNPs in mice to neutralize SARS-CoV-2 variants delta (B.1.617) and alpha (B.1.1.7) variants.

* Corresponding author at: Department of Medical Nanotechnology, Faculty of Advanced Sciences and Technology, Tehran Medical Science, Islamic Azad University, Tehran, Iran.
E-mail address: alijebal2011@gmail.com (A. Jebali).

https://doi.org/10.1016/j.intimp.2021.108231
Received 27 July 2021; Received in revised form 22 September 2021; Accepted 4 October 2021
Available online 7 October 2021
1567-5769/© 2021 Elsevier B.V. All rights reserved.
2. Materials and methods

2.1. Plasmid construct

To synthesize the saRNA construct, a common bacterial plasmid vector with a T7 promoter was used. The required sequence for saRNA construct was synthesized and sub-cloned by Biomatik, Canada. Based on (Fig. 1a), saRNA construct has 5′ UTR (GenBank accession number: NC_001449), nsP1-4 (GenBank accession number: NC_001449), sub-genomic promoter (GenBank accession number: NC_001449), S-protein (GenBank accession number: MZ571142.1), 5′ UTR (GenBank accession number: NC_001449), and polyA tail. The negative control construct (Fig. 1b) has the same structure except for the sub-genomic promoter and the S-protein coding sequence. Positive control construct (Fig. 1c) has 4 main parts, including 5′ UTR (GenBank accession number: NC_001449), S-protein (GenBank accession number: MZ571142.1), 3′ UTR (GenBank accession number: NC_001449), and polyA tail. Supplementary 1 shows the full length sequence of saRNA construct used in this study.

2.2. Synthesis of linear saRNA

The plasmid encoding saRNA construct was transformed into E. coli (institute Pasteur, Iran), cultured in Luria Broth with 100 μg/mL carbenicillin (Sigma Aldrich, UK). Plasmids were purified using a Plasmid Plus MaxiPrep kit (QIAGEN, UK) and their concentration and purity were measured on a NanoDrop spectrophotometer (ThermoFisher, UK). Then, cloned plasmids were linearized using MluI for 3 h at 37 °C. Then, saRNA transcripts were produced using 1 μg of linearized DNA template in a MEGAScript™ reaction (Ambion, UK) for 1 h at 37 °C. One μg linear saRNA was mixed with 1 μM ScriptCap™ (CellScript, WI, USA) for 1 h at 37 °C. Synthesized saRNA was purified by LiCl precipitation, resuspended in RNA storage buffer, and stored at −80 °C. To evaluate the purity of synthesized saRNA, the A260/A280 ratio was measured using the NanoDrop spectrophotometer (ThermoFisher, UK) [21].

2.3. Encapsulation of saRNA in LNPs

To encapsulate saRNA, we used a simple chemical process [21] in which 0.1, 1, and 10 μg of purified saRNA were separately mixed with an ethanolic lipid mixture of 1,2-dilinoleyl oxy-3-dimethylaminopropane, 1,2-diastearoyl-sn-glycero-3-phosphocholine, cholesterol, and 1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 at a ratio of 10:48:2:40 at pH 4.0. The mixture was vigorously stirred by a T-mixer and then placed in a dialysis bag to purify overnight. Then, the size distribution and zeta potential of the produced LNPs were determined.

Fig. 1. The schematic diagrams of saRNA (a), negative control (b), and positive control construct (c). Abbreviation: 7-Methylguanosine (m7G); Untranslated region (UTR); Non-structural protein (nsP), Spike protein (s-protein). The size distribution (d) and zeta potential (e) of saRNA LNPs by DLS apparatus. HEK293T/17 cells were treated with saRNA LNPs at 0.1–10 μg and the expression of S-protein was evaluated by Real-time PCR (f) and ELISA (g). All data were shown as mean ± SD. * indicates significance difference with P < 0.05 when compared with negative controls using a one-way ANOVA adjusted for multiple comparisons with n = 5.
by dynamic light scattering (DLS) (Malvern Instruments Ltd, Malvern, UK). The encapsulation of saRNA was confirmed by gel electrophoresis and the entrapment efficiency was measured by a NanoDrop spectrophotometer (ThermoFisher, UK) at 260 nm. For positive and negative controls, the same encapsulation process was also performed.

2.4. The expression of saRNA in HEK293T/17 cells

In Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco) containing 10% fetal bovine serum (FBS) (Gibco), 1% L-glutamine (Thermo Fisher Scientific), and 1% penicillin–streptomycin (Thermo Fisher Scientific), HEK293T/17 cells were cultured at 37 °C for 5 days. Then, cells were separately incubated with 0.1–10 μg saRNA, negative control, and positive control LNPs. After 24 h, the expression of S-protein was confirmed by Real-time PCR and ELISA (Supplementary 2).

2.5. Immunization

All procedures related to animal experiments used in this section were approved by the ethical committee of Sirjan School of Medical Sciences, Sirjan, Iran (Ethical code: IR.SIRUMS.REC.1400.001). We used 10 BALB/c mice aged 6–8 weeks in each study group and they were orally immunized with 0.1, 1, and 10 μg saRNA LNPs at weeks 1 and 3. For each mouse, 100 μL of vaccine mixture was orally administered using a needle-free insulin syringe. In the control groups, BALB/c mice were orally immunized with 10 μg positive control LNPs and 10 μg negative control LNPs at weeks 1 and 3 as described. Serum samples were collected at weeks 2, 4, and 6 and the spleen of vaccinated mice was removed at week 6.

2.6. Recovered COVID-19 patient samples

Here, the serum samples of recovered COVID-19 patients (n = 10) were obtained from Zahedan University of Medical Sciences, Zahedan, Iran. All of them had been infected with the delta variant. Written informed consent was given from all participants (ethical codes: IR.ZAUMS.REC.1399.317 and IR.ZAUMS.REC.1399.316). All recovered patients showed a negative PCR test at the time of sampling.

2.7. Serum levels of antibodies in mice and recovered COVID-19 patients

A semi-quantitative ELISA was used to determine the levels of IgG, IgG1, IgG2a, and IgA antibodies in the sera of vaccinated mice. Also, the levels of IgG and IgA antibodies were determined in the sera of recovered COVID-19 patients.

First, high binding ELISA plates (Biomat, Italy) were coated with SARS-CoV-2 S-protein recombinant antigen (Sigma-Aldrich) at 1 μg/mL. After washing plates, 50 μL of diluted serum samples collected from immunized mice and recovered COVID-19 patients were separately added to wells. After incubation for 1 h at 37 °C, plates were washed with PBS and then 100 μL of the following secondary antibody was separately added: 1) anti-mouse IgG-HRP, 2) anti-mouse IgG1-HRP, 3) anti-mouse IgG2a-HRP, 4) anti-mouse IgA-HRP, 5) anti-human IgG-HRP, 6) anti-human IgA-HRP (Southern Biotech). After incubation and washing with PBS, 50 μL of 3,3′, 5,5′-tetramethylbenzidine was added and then the reactions was stopped by adding 50 μL of 10% sulfuric acid. Finally, the absorbance of each well was read by a Spectrophotometer at 450 nm (BioTek Industries) and serum levels of antibodies was measured using a standard curve.

2.8. Wild-type viral neutralization assay

To evaluate the ability of vaccinated mice or recovered COVID-19 patients to neutralize SARS-CoV-2 virus, wild-type viral neutralization assay was applied according to McKey et al [21]. SARS-CoV-2 variant B.1.1.7 and variant B.1.617 were first isolated from COVID-19 patients. Then, they were cultured on Caco2 cells in DMEM (Gibco) containing 10% FBS (Gibco), 1% L-glutamine (Thermo Fisher Scientific), and 1% penicillin–streptomycin (Thermo Fisher Scientific) for 5 days at 37 °C. Finally, propagated viruses were purified by Caesium chloride gradient centrifugation. In the next step, all sera were first incubated at 56 °C for 30 min and were serially diluted in DMEM (Gibco, Thermo Fisher Scientific) with 1% penicillin–streptomycin (Thermo Fisher Scientific), and 0.3% BSA fraction V (Thermo Fisher Scientific). Serum dilutions were separately incubated with 100 TCID50 per well of SARS-CoV-2 variant B.1.1.7 and variant B.1.617 for 1 h at room temperature. Then, they were transferred to 96-well plates pre-seeded with HEK293T/17 cells and incubated at 37 °C for 5 days. After incubation, 100 μL of crystal violet (Sigma-Aldrich) was added to each well and scored for cytopathic effect. The neutralization titer was calculated as the reciprocal of the highest serum dilution at which full virus neutralization occurred.

2.9. IFN-γ ELISpots

Based on the Mouse IFN-γ ELISpotPLUS kit (Mabtech), anti-IFN-γ-pre-coated plates were first blocked with 10% FBS (Gibco), and then 2.5 × 10^5 splenocytes of vaccinated mice and 1 μg/mL SARS-CoV-2 peptides (AGX819, Sigma-Aldrich) were added. Plates were incubated overnight at 37 °C and 5% CO2. After incubation, biotinylated cytokine-specific detection antibodies (Mabtech), streptavidin-enzyme conjugate (Mabtech), and substrate (Mabtech) were added. Finally, each well was examined under an optical microscope (Zeiss, Germany) and the number of stained cells was calculated.

2.10. Secretion of IL-6 and TNF-α

The level of IL-6 and TNF-α in serum samples of immunized mice, recovered COVID-19 patients, and the supernatant of activated splenocytes was measured by ELISA kit. Briefly high binding ELISA plates (Biomat, Italy) were separately coated with anti-mouse and anti-human IL-6 and TNF-α (Southern Biotech) and then the corresponding samples were separately added. After incubation for 1 h at 37 °C, plates were washed by PBS, and then 100 μL of secondary antibodies, including anti-mouse IL-6-HRP (Southern Biotech), anti-human IL-6-HRP (Southern Biotech), anti-mouse TNF-α-HRP (Southern Biotech), and anti-human TNF-α-HRP (Southern Biotech) were added. Then, 50 μL of 3,3′, 5,5′-tetramethylbenzidine was added and incubated for 15 min at room temperature. Finally, the reaction was stopped by adding 50 μL of 10% sulfuric acid and the absorbance of each well was read by a Spectrophotometer at 450 nm (BioTek Industries). The level of IL-6 and TNF-α was determined by a standard curve.

2.11. Statistical analysis

GraphPad Prism (version 8.4) was used to prepare graphs and statistics. One-way ANOVA was used and P values<0.05 were considered significant (with n = 10 biologically independent mice and n = 10 recovered COVID-19 patients). All data are shown as mean ± standard deviation (SD).

3. Results

3.1. LNP characterization

Synthesized linear saRNA was encapsulated in LNPs and then characterized. The average particle size and zeta potential of saRNA LNPs were 100 ± 5 nm and −22 ± 0.6 mV, respectively (Fig. 1d and Fig. 1e). The highest entrapment efficiency of saRNA was 67 ± 2%.

3.2. The expression of S-protein

Before immunization of mice with saRNA LNPs, their efficacy was
verified in HEK273T/17 cells. High expression of S-protein was observed at both mRNA and protein levels after transfection of HEK293T/17 cells with saRNA LNPs (Fig. 1f and Fig. 1g). It was found that the relative expression of S-protein was increased with increasing LNP dose.

3.3. Serum levels of IgG, IgG1, IgG2a, and IgA antibodies

BALB/c mice were orally immunized with 0.1–10 µg saRNA LNPs at weeks 1 and 3 and their serum samples were then collected at weeks 2, 4, and 6. ELISA assay showed a high quantity of SARS-CoV-2 specific IgG, IgG1, IgG2a, and IgA antibodies in a dose-dependent manner in serum of mice (Fig. 2a-c). Interestingly the levels of IgG and IgA antibodies in mice immunized with 10 µg saRNA LNPs was almost close to antibody levels in recovered COVID-19 patients (P > 0.05). Here, significant differences were found between the level of antibodies in vaccinated mice or recovered COVID-19 patients and negative control (P < 0.05). A Th1/Th2 skewing response (Fig. 2d) was also observed in mice vaccinated with positive control and 0.1–10 µg of saRNA LNPs. It means that all mice vaccinated with saRNA LNPs and positive control LNPs showed a Th1-biased response.

3.4. Wild-type viral neutralization assay

SARS-CoV-2 variants B.1.1.7 and B.1.617 were isolated and cultured on Caco2 cells. In the next step, serum dilutions were separately incubated with 100 TCID50 per well of both SARS-CoV-2 variants. Then, they were transferred to pre-seeded well with HEK293T/17 cells and incubated for 5 days. After incubation, the cytopathic effect was recorded and the neutralization titer was calculated. We observed a high viral neutralization titer in mice vaccinated with saRNA LNPs at 0.1–10 µg in a linear dose-dependent manner. We also found that the secreted antibodies induced by saRNA LNPs could neutralize both SARS-CoV-2 variants B.1.1.7 (alpha) and B.1.617 (delta) (Fig. 3a-b). Interestingly, secreted antibodies detected in recovered COVID-19 patients could neutralize both variants. A significant positive correlation was observed between SARS-CoV-2 specific IgG and SARS-CoV-2 neutralization titer in both vaccinated mice and recovered COVID-19 patients (Fig. 3c-d).

3.5. Cellular and cytokine responses

Splenocytes of vaccinated mice were first activated with SARS-CoV-2 peptides and then added to anti-IFN-γ-pre-coated plates. After incubation for overnight at 37 °C, detection antibodies, streptavidin-enzyme conjugate, and substrate were added. Finally, each well was examined under an optical microscope and the number of stained cells was calculated. We found that re-stimulated splenocytes of vaccinated mice had a high IFN-γ secretion in a linear dose-dependent manner (Fig. 4a). There was a significant difference between mice vaccinated with 10 µg saRNA LNPs and other groups (P < 0.05).

We also measured the secretion of IL-6 and TNF-α by re-stimulated splenocytes and the serum levels of IL-6 and TNF-α in vaccinated mice and recovered COVID-19 patients. It was shown that in both supernatants of re-stimulated splenocytes and vaccinated mouse sera, there was a high level of IL-6 and TNF-α in a dose-dependent manner (Fig. 4b-e). Here, significant differences were observed between mice vaccinated with 10 µg saRNA LNPs and other vaccinated groups (P < 0.05). We found significant differences between the level of IL-6 and TNF-α in the serum of recovered COVID-19 patients compared with vaccinated mice by saRNA LNPs (P < 0.05).

4. Discussion

In this study, we sought to develop a saRNA-based oral vaccine that could simultaneously fight both the SARS-COV-2 variants B.1.1.7 (alpha) and B.1.617 (delta). Vaccines based on saRNA have already been used for some infectious diseases [14,22]. This technology has also been studied for COVID-19, showing some advantages versus conventional mRNA [21,23]. The strength of saRNA-based vaccines is that they can induce potent immune responses at low doses because of their self-
replicating property. Of course, these vaccines, like other vaccines, may have side effects and must be evaluated. Currently, although various vaccines against SARS-COV-2 are designed with different platforms [24], most people of un-developed and developing countries still have not been vaccinated, which can be due to various reasons, such as economic and social problems [20]. Unfortunately, the genomic structure of SARS-COV-2 is not stable and it is susceptible to mutations [25]. This phenomenon leads to a significant reduction of vaccine efficacy with any platform [26].

In this study, the designed saRNA had alphavirus replicase, RDRP, as well as the gene coding for the S-protein. The replicase was required for saRNA amplification and mediates the production of this RNA [27]. This leads to the production of a large number of S-proteins that be taken up by antigen presenting cells (APCs). Of course, it should be noted that saRNAs, in order to efficiently be delivered to cells, must be protected. One of the best ways is to use LNPs [21] and they can be optimized for target cells [28]. We first tested the efficacy of saRNAs in HEK293T cells and then in mice. The high expression of S-protein at both mRNA and protein levels was observed after transfection of HEK293T/17 cells. This valuable finding gave us hope that the saRNA LNPs might stimulate the immune system and could act as an effective vaccine. In this study, the vaccine was orally administered because our goal was to stimulate the immune cells located in the mucosa. Oral administration is much easier than injectable vaccines and is especially more acceptable by children. After vaccination of mice with saRNA LNPs, we saw high levels of IgG, IgG1, IgG2a, and IgA antibodies against SARS-CoV-2 in a dose-dependent manner. Interestingly, the concentration of IgG and IgA antibodies in the serum of recovered COVID-19 patients was approximately equal to antibody concentration in the serum of mice vaccinated with saRNA LNPs at 10 μg. Another important finding was Th1/Th2 skewing or Th1-biased response. Moreover, a high viral neutralization titer was seen in mice vaccinated with saRNA LNPs at 0.1–10 μg and in recovered COVID-19 patients. Interestingly, these antibodies could neutralize both variants of SARS-CoV-2 and this shows that the designed system (saRNA LNPs) has been fully expressed. Importantly, re-stimulated splenocytes of vaccinated mice showed a high IFN-γ secretion in a linear, dose-dependent manner. Supernatants of re-stimulated splenocytes and vaccinated mouse sera contained a high level of IL-6 and TNF-α in a dose-dependent manner.

Before us, McKay et al. had shown that saRNA SARS-CoV-2 LNP vaccine induces remarkably high and dose-dependent SARS-CoV-2 specific antibody titers in mouse sera, as well as robust neutralization of both a pseudo-virus and wild-type virus [21]. Also, Spencer et al showed vaccination with saRNA and adenoviral COVID vaccines induce robust immune responses in mice. They demonstrated that two-dose heterologous vaccination was better than single-dose. Neutralizing titers after heterologous prime-boost were at least comparable or higher than the titers measured after homologous prime-boost vaccination with viral vectors [23]. It is important to know the intestinal immune responses against SARS-CoV-2 is more effective than others [29]. Some studies on

![Fig. 3. The viral neutralization titer against SARS-CoV-2 variants B.1.1.7 (a) and B.1.617 (b) in mice vaccinated with 0.1–10 μg saRNA LNPs and recovered COVID-19 patients. A significant positive correlation was seen between SARS-CoV-2 specific IgG and SARS-CoV-2 neutralization titer of secreted antibodies against SARS-CoV-2 variants B.1.1.7 (c) and B.1.617 (d) in both vaccinated mice and recovered COVID-19 patients. * indicates significance difference at p < 0.05 when compared with negative control using a one-way ANOVA adjusted for multiple comparisons with n = 10 biologically independent mice and recovered COVID-19 patients.](image-url)
COVID-19 animal models [30] and COVID-19 patients with gastrointestinal symptoms [31] revealed that intraepithelial CD8+ lymphocytes and lamina propria residing CD4+ and CD8+ effector T cells are significantly expanded compared with healthy controls [32]. Importantly, inflammatory dendritic cells are significantly reduced in the lamina propria of COVID-19 patients with gastrointestinal symptoms [32]. These data suggest that intestinal infection with SARS-CoV2 alters immune signatures and leads to a more favorable immune response. Interestingly, the serum levels of IL-6 and IL-17 are lower in COVID-19 patients with GI symptoms compared with COVID-19 patients without GI symptoms. Another interesting point is that the presence of the virus in the GI tract may trigger a long-term production of anti-viral IgA antibodies, compared with IgG and IgM antibodies [33,34].

Taken together, the oral vaccine, based on saRNA LNPs, could induce a Th1-biased response to produce a high quantity of SARS-CoV-2 specific IgG and IgA antibodies. We also found that the produced antibodies could neutralize SARS-CoV-2 variants B.1.1.7 (alpha) and B.1.617 (delta).

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We thank Dr. Cristian Smerdou (Cima Universidad de Navarra, Spain) and PD. Dr. Vladimir Temchura, Institute of Clinical and Molecular Virology, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany for valuable helps. We thank the Zahedan University of Medical Sciences, Zahedan, Iran for providing sera from recovered COVID-19 patients.

Funding

This work was financially supported by Sirjan School of Medical Sciences, Sirjan, Iran (grant number: 99000071).

Ethical approval

All experiments were under the guidelines of the National Institute of Health, the provisions of the Declaration of Helsinki, and the ethics committee of Sirjan School of Medical Sciences, Sirjan, Iran. (Ethical code: IR.SIRUMS.REC.1400.001).

Informed consent

Informed consent was obtained from all individuals included in this study.
Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.intimp.2021.108231.

References

[1] C. D’Amico, F. Fontana, R. Cheng, H.A. Santus, Development of vaccine formulations: past, present, and future, Drug Delivery and Translational Research 11 (2) (2021) 353–372.
[2] Y. Shen, T. Hao, S. Ou, C. Hu, L. Chen, Applications and perspectives of nanomaterials in novel vaccine development, MedChemComm 9 (2) (2018) 226–238.
[3] K. Kumaragurubaran, K. Kaliaperumal, DNA vaccine: the miniature miracle, Veterinary World 6 (3) (2013) 228, https://doi.org/10.3255/vetworld.2013.228-232.
[4] D. Hobenik, M. Bros, DNA vaccines—how far from clinical use? J. Mol. Sci. 19 (11) (2018) 3605.
[5] E. Gilboa, J. Vieweg, Cancer immunotherapy with mRNA-transfected dendritic cells, Immunol. Rev. 199 (1) (2004) 251–263.
[6] T. Schläke, A. Then, M. Thran, I. Jordan, mRNA as novel technology for passive immunotherapy, Cell. Mol. Life Sci. 76 (2) (2019) 301–328.
[7] F.P. Polack, S.J. Thomas, N. Kirchin, J. Abbalon, A. Gutman, S. Lockhart, J. L. Perez, G. Perez Marc, E.D. Moreira, C. Zerbini, R. Bailey, K.A. Swanson, S. Roychoudhury, K. Koury, P. Li, W.V. Kalina, D. Cooper, R.W. Freund, L. L. Hammitt, O. Türeci, H. Nell, A. Schaefer, S. Ünal, D.B. Tresnan, S. Mather, P.F. McKay, B.I. Yus, Y. Aldon, R.J. Shattock, Inside out: the promise of self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice, Nat. Commun. 11 (1) (2020), https://doi.org/10.1038/s41467-020-17409-9.
[8] K. Luisi, K.M. Morabito, K.E. Burgomaster, M. Sharma, W.-P. Kong, B.M. Foreman, K. Samnuan, A.K. Blakney, D. Wright, H.R. Sharpe, C. Gilbride, A. Truby, E. R. Allen, S.C. Gilbert, R.J. Shattock, T. Lambe, Hormone replacement vaccines in genetic therapy for the SARS-CoV-2 vaccine candidate induces high neutralizing antibody titers in mice, Mater. Sci. Eng. C 103 (2020) 110566.
[9] J.Y. Noh, H.W. Jeong, E.-C. Shin, SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern, Signal Transduction and Targeted Therapy 6 (1) (2021) 1–2.
[10] J. Kim, Y. Egyeri, M. Gupta, G. Sahay, Self-assembled mRNA vaccines, Adv. Drug Deliv. Res. 170 (2021) 85–112.
[11] A.K. Blakney, P.F. McKay, B.I. Yu, R.J. Shattock, Inside out: optimization of lipid nanoparticle formulations for new complex and in vivo delivery of mRNA, Gene Ther. 26 (9) (2019) 363–372.
[12] C. Weidinger, A.N. Hegazy, R. Glubek, B. Siegmund, COVID-19—from mucosal immunology to IBD patients, Mucosal Immunol. 14 (3) (2021) 566–573.
[13] S.F. Xia, L.-M. Yan, A.W.H. Chin, K. Feng, K.-T. Choy, A.Y.L. Wong, P. Kaeppewceede, R.A.P.M. Perera, L.L.M. Poon, J.M. Nicholls, M. Peiris, H.-J. Yen, Pathogenesis and transmission of SARS-CoV-2 in golden hamsters, Nature 583 (7818) (2020) 834–838.
[14] W.K. Leung, K.-F. To, P.K. Chan, H.L. Chan, A.K.W. Kw, N. Lee, K.Y. Yuen, J.J. Sung, Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection, Gastroenterology 125 (4) (2003) 1011–1017.
[15] A.E. Livanos, D. Jha, F. Cossarini, A.S. Gonzalez-Reiche, M. Tokuyama, T. Aydillo, S. Mather, P.E. Yang, R.S. Pelc, K.A. Dowd, D. O'Hagan, J. Ulmer, S. Mostman, A. Sambor, E. Lepine, J.R. Mascola, T.C. Pierson, B.S. Graham, D. Yu, Development of a potent Zika virus vaccine using self-assembling messenger RNA, Sci. Adv. 6 (32) (2020) eaba5068, https://doi.org/10.1126/sciadv.aba5068.
[16] A.J. Spencer, P.F. McKay, A. Sambor, J. Ulmer, S. Mostman, A. Sambor, F. Giusti, A. Bonci, M. Taccone, C. Gallorini, I. Ferlenghi, D.T. O'Hagan, C. Pergola, B. C. Baudnner, R. Adamo, Mannosylation of LNP results in improved potency for self-amplifying RNA (SAM) vaccines, ACS Infect. Dis. 5 (9) (2019) 1546–1558.
[17] K. Lundstrom, The Potential of Self-amplifying RNA Vaccines for Infectious Diseases and COVID-19, Vaccine Research 7 (1) (2020) 25–37.
[18] A.K. Blakney, S. Ip, A.J. Geall, An update on self-amplifying mRNA vaccine development, Vaccines 9 (2) (2021) 97.
[19] C. Jentsch, M. Anand, C.T. Bauch, Prioritizing COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study, Lancet. Infect. Dis. (2021).
[20] P.F. McKay, K. Hu, A.K. Blakney, K. Samaan, J.C. Brown, R. Penn, J. Zhou, C. R. Bouton, P. Rogers, K. Polra, J.C.L. Cin, B. Barbosa, Y.K. Tam, W.S. Barclay, R. J. Shattock, Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice, Nat. Commun. 11 (1) (2020), https://doi.org/10.1038/s41467-020-17409-9.
[21] L. Hammitt, L. Perez, G. Pizzo Marc, E.D. Moreira, C. Zerbini, R. Bailey, K.A. Swanson, S. Roychoudhury, K. Koury, P. Li, W.V. Kalina, D. Cooper, R.W. Freund, L. L. Hammitt, O. Türeci, H. Nell, A. Schaefer, S. Ünal, D.B. Tresnan, S. Mather, P.F. McKay, B.I. Yus, Y. Aldon, R.J. Shattock, T. Lambe, Hormone replacement vaccines in genetic therapy for the SARS-CoV-2 vaccine candidate induces high neutralizing antibody titers in mice, Mater. Sci. Eng. C 103 (2020) 110566.